Procore stock price target raised to $90 from Goldman Sachs on stabilizing growth
Investing.com - Hims and Hers (NYSE:HIMS) maintained its Buy rating and $85.00 price target at BTIG following the company’s third-quarter earnings report released Monday. The telehealth company’s stock has delivered an impressive 113.82% return over the past year, according to InvestingPro data.
The telehealth provider reported revenue of $599 million for the quarter, representing 49% year-over-year growth and exceeding both company guidance of $570-590 million and consensus estimates of $580 million. Adjusted EBITDA reached $78.4 million, a 53% increase year-over-year, surpassing guidance of $60-70 million. This strong performance aligns with the company’s remarkable 88.69% revenue growth over the last twelve months, with total revenue reaching $2.01 billion in that period.
Hims and Hers narrowed its full-year 2025 guidance ranges for both revenue and adjusted EBITDA while maintaining its projection of at least $725 million in revenue from weight management services this year. The company reaffirmed its long-term goals of reaching $6.5 billion in revenue and $1.3 billion in EBITDA by 2030. InvestingPro analysis indicates the company is currently trading at a high earnings multiple with a P/E ratio of 57.01, reflecting market expectations for continued strong growth.
BTIG highlighted the company’s ongoing discussions with Novo Nordisk (NYSE:NVO) regarding potential distribution of Wegovy injections and oral medications. The firm also noted Hims and Hers’ international expansion plans targeting Canada, Brazil, Australia, Japan, and European markets.
The telehealth company is broadening its service offerings to include comprehensive home testing, early cancer detection through a partnership with GRAIL, and additional treatment areas including low testosterone, menopause, and whole-body testing.
In other recent news, Hims & Hers Health reported its third-quarter 2025 earnings, showing a mixed financial performance. The company missed analysts’ expectations with an earnings per share (EPS) of $0.06, falling short of the projected $0.10. However, revenue surpassed expectations, reaching $600 million compared to the forecasted $580.37 million. This represents a positive revenue surprise of 3.38%. Canaccord Genuity reiterated its Buy rating for Hims & Hers Health, maintaining a price target of $68. This decision follows the company’s strong subscriber growth, with a 40% year-over-year increase in subscribers, excluding on-demand sexual health. Multi-condition subscribers grew by 80% year-over-year, now making up 20% of total subscribers. These developments highlight successful cross-selling of treatments within the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.